Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
CAMBRIDGE, Mass., Nov. 13, 2017 -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections, today announced that the underwriters of its previously announced initial public offering have exercised their option to purchase an additional 471,498 shares during the option period. Including the option exercise, total gross proceeds from the offering of an aggregate of 5,971,498 shares were approximately $83.6 million, before deducting the underwriting discount and estimated offering expenses payable by Spero. This represents approximately $6.6 million more gross proceeds than the gross proceeds on the initial closing. Spero’s common stock began trading on The Nasdaq Global Select Market on November 2, 2017 under the symbol “SPRO”.
BofA Merrill Lynch, Cowen and Stifel acted as joint book-running managers for the offering. Oppenheimer & Co. acted as a co-manager for the offering.
A registration statement relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission. The offering was made by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained from BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email at [email protected]; from Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, or by telephone at (631) 274-2806; and from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, or by telephone at (415) 364-2720 or by email at [email protected].
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Spero
Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections.
Spero Media and Investor Contact
Sharon Klahre
Director, Investor Relations
857-242-1547
[email protected]
